 
Ansun Biopharma, Inc.
NEWS
        
        
        
    
        Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.
    
        
    
        
    
        
    
        BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
    
        
    
        
    
        
    
        Ansun Biopharma closed on a Series A financing round worth $85 million. The company plans to use the funds raised for a Phase III clinical trial of its experimental anti-viral drug, DAS181.
    
        
    
        
    
        
    IN THE PRESS
        
        
        
    JOBS
        
        
        
     
         
 
 
